{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:23:50Z","timestamp":1793301830306,"version":"4.5.0"},"reference-count":118,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Liver transplantation is a treatment option for nonresectable patients with early-stage HCC, with more significant advantages when Milan criteria are fulfilled. An immunosuppressive regimen is required to reduce the risk of graft rejection after transplantation, and CNIs represent the drugs of choice in this setting. However, their inhibitory effect on T-cell activity accounts for a higher risk of tumour regrowth. mTOR inhibitors (mTORi) have been introduced as an alternative immunosuppressive approach to conventional CNI-based regimens to address both immunosuppression and cancer control. The PI3K-AKT-mTOR signalling pathway regulates protein translation, cell growth, and metabolism, and the pathway is frequently deregulated in human tumours. Several studies have suggested the role of mTORi in reducing HCC progression after LT, accounting for a lower recurrence rate. Furthermore, mTOR immunosuppression controls the renal damage associated with CNI exposure. Conversion to mTOR inhibitors is associated with stabilizing and recovering renal dysfunction, suggesting an essential renoprotective effect. Limitations in this therapeutic approach are related to their negative impact on lipid and glucose metabolism as well as on proteinuria development and wound healing. This review aims to summarize the roles of mTORi in managing patients with HCC undergoing LT. Strategies to overcome common adverse effects are also proposed.<\/jats:p>","DOI":"10.3390\/curroncol30060421","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T02:59:57Z","timestamp":1686279597000},"page":"5574-5592","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"30","author":[{"given":"Letizia","family":"Todeschini","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Surgery, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cristin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4016-534X","authenticated-orcid":false,"given":"Alessandro","family":"Martinino","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Illinois Chicago, Chicago, IL 60607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Mattia","sequence":"additional","affiliation":[{"name":"General Surgery and Liver Transplantation Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Agnes","sequence":"additional","affiliation":[{"name":"General Surgery and Liver Transplantation Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3392-9292","authenticated-orcid":false,"given":"Francesco","family":"Giovinazzo","sequence":"additional","affiliation":[{"name":"General Surgery and Liver Transplantation Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and Management of Hepatocellular Carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cristin, L., Montini, A., Martinino, A., Scarano Pereira, J.P., Giovinazzo, F., and Agnes, S. (2023). The Role of Growth Hormone and Insulin Growth Factor 1 in the Development of Non-Alcoholic Steato-Hepatitis: A Systematic Review. Cells, 12.","DOI":"10.3390\/cells12040517"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3748\/wjg.v25.i21.2591","article-title":"Liver transplantation for hepatocellular carcinoma: Where do we stand?","volume":"25","author":"Santopaolo","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajt.13197","article-title":"OPTN\/SRTR 2013 Annual Data Report: Liver","volume":"15","author":"Kim","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.12-11-1321","article-title":"Liver transplantation for hepatocellular carcinoma in Asia","volume":"12","author":"Lo","year":"2007","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/cncr.11266","article-title":"Expression and prognostic role of tumor suppressor gene PTEN\/MMAC1\/TEP1 in hepatocellular carcinoma","volume":"97","author":"Hu","year":"2003","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ferr\u00edn, G., Guerrero, M., Amado, V., Rodr\u00edguez-Per\u00e1lvarez, M., and De la Mata, M. (2020). Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041266"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1001\/jamaoncol.2019.2525","article-title":"Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?","volume":"5","author":"Unni","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory Functions of mTOR Inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clinre.2017.10.001","article-title":"Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity","volume":"42","author":"Ghazal","year":"2018","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.transproceed.2008.03.165","article-title":"Sirolimus-Based Immunosuppression Therapy in Liver Transplantation for Patients with Hepatocellular Carcinoma Exceeding the Milan Criteria","volume":"40","author":"Zhou","year":"2008","journal-title":"Transplant. Proc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1399-0012.2009.01040.x","article-title":"Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients","volume":"23","author":"Rogers","year":"2009","journal-title":"Clin. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.transproceed.2010.04.045","article-title":"Sirolimus in Liver Transplant Recipients: A Large Single-Center Experience","volume":"42","author":"Vivarelli","year":"2010","journal-title":"Transplant. Proc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/lt.22434","article-title":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation","volume":"18","author":"Bustamante","year":"2012","journal-title":"Liver Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial","volume":"12","author":"Nevens","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus after Liver Transplantation\u2014PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1016\/j.transproceed.2014.08.045","article-title":"Everolimus-Based Immunosuppression in Patients with Hepatocellular Carcinoma at High Risk of Recurrence after Liver Transplantation: A Case Series","volume":"46","author":"Ferreiro","year":"2014","journal-title":"Transplant. Proc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus Use in Liver Transplant Recipients with Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/lt.25191","article-title":"Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence","volume":"24","author":"Jung","year":"2018","journal-title":"Liver Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0000000000002955","article-title":"Experience with Early Sorafenib Treatment with mTOR Inhibitors in Hepatocellular Carcinoma Recurring after Liver Transplantation","volume":"104","author":"Invernizzi","year":"2020","journal-title":"Transplantation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/lt.25879","article-title":"Time to Conversion to an Everolimus-Based Regimen: Renal Outcomes in Liver Transplant Recipients from the EVEROLIVER Registry","volume":"26","author":"Saliba","year":"2020","journal-title":"Liver Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR Inhibition Is Most Beneficial after Liver Transplantation for Hepatocellular Carcinoma in Patients with Active Tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.transproceed.2020.02.058","article-title":"Immunosuppressive Treatment with mTOR Inhibitors for Malignancies after Liver Transplantation: Long-Term Survival Retrospective Analysis","volume":"52","author":"Valenzuela","year":"2020","journal-title":"Transplant. Proc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e709","DOI":"10.1097\/TXD.0000000000001159","article-title":"Renal Protective Effect of Everolimus in Liver Transplantation: A Prospective Randomized Open-Label Trial","volume":"7","author":"Kadry","year":"2021","journal-title":"Transplant. Direct"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13897","article-title":"High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients","volume":"34","author":"Nitta","year":"2021","journal-title":"Transpl. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","volume":"22","author":"Colmenero","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e937988-1","DOI":"10.12659\/AOT.937988","article-title":"Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma","volume":"27","author":"Sapisochin","year":"2022","journal-title":"Ann. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/LVT.0000000000000003","article-title":"Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: A multicenter, randomized, controlled trial","volume":"29","author":"Mulder","year":"2023","journal-title":"Liver Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11912-012-0227-y","article-title":"PI3K and mTOR signaling pathways in cancer: New data on targeted therapies","volume":"14","author":"Willems","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fcell.2015.00024","article-title":"Nuclear PI3K signaling in cell growth and tumorigenesis","volume":"3","author":"Davis","year":"2015","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","article-title":"The mTOR Signalling Pathway in Human Cancer","volume":"13","author":"Lopes","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Fu, W., and Hall, M.N. (2020). Regulation of mTORC2 Signaling. Genes, 11.","DOI":"10.3390\/genes11091045"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1111\/bph.12749","article-title":"Therapeutic targeting of the mTOR-signalling pathway in cancer: Benefits and limitations","volume":"171","author":"Moschetta","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_40","first-page":"ra42","article-title":"The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis","volume":"5","author":"Petit","year":"2012","journal-title":"Sci. Signal."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ccell.2017.11.011","article-title":"mTORC2 Promotes Tumorigenesis via Lipid Synthesis","volume":"32","author":"Guri","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41419-019-1828-2","article-title":"mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces hepatocellular carcinoma","volume":"10","author":"Li","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"ra24","DOI":"10.1126\/scisignal.2002739","article-title":"Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice","volume":"5","author":"Menon","year":"2012","journal-title":"Sci. Signal."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.26323","article-title":"The mTOR Pathway in Hepatic Malignancies","volume":"58","author":"Bhat","year":"2013","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal role of mTOR signaling in hepatocellular carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","article-title":"Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends","volume":"60","author":"Matter","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12032-009-9201-4","article-title":"The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma","volume":"27","author":"Zhou","year":"2010","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.3748\/wjg.v13.i37.4974","article-title":"Alcohol-induced steatosis in liver cells","volume":"13","author":"Donohue","year":"2007","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7150\/ijms.25393","article-title":"Chronic Alcohol Consumption Inhibits Autophagy and Promotes Apoptosis in the Liver","volume":"15","author":"Menk","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Guerrero, M., Ferr\u00edn, G., Rodr\u00edguez-Per\u00e1lvarez, M., Gonz\u00e1lez-Rubio, S., S\u00e1nchez-Fr\u00edas, M., Amado, V., Pozo, J.C., Poyato, A., Ciria, R., and Ayll\u00f3n, M.D. (2019). mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020336"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(89)90417-0","article-title":"Rapamycin for Immunosuppression in Organ Allografting","volume":"334","author":"Calne","year":"1989","journal-title":"Lancet"},{"key":"ref_52","first-page":"2177","article-title":"Sirolimus approved with renal transplant indication","volume":"56","author":"Miller","year":"1999","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/nov152","article-title":"Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex","volume":"17","author":"MacKeigan","year":"2015","journal-title":"Neuro-Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical Pharmacokinetics of Sirolimus","volume":"40","author":"Mahalati","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.3748\/wjg.v21.i39.11185","article-title":"Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review","volume":"21","author":"Angelis","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/17474124.2021.1823213","article-title":"Recurrence of hepatocellular carcinoma following liver transplantation","volume":"15","author":"Hoffman","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.trre.2015.02.003","article-title":"mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?","volume":"29","author":"Duvoux","year":"2015","journal-title":"Transplant. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.21037\/tgh.2016.03.18","article-title":"Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence","volume":"1","author":"Khorsandi","year":"2016","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.3748\/wjg.v12.i45.7319","article-title":"Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients","volume":"12","author":"Res","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y","article-title":"Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation","volume":"68","author":"Yokoyama","year":"1991","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.TP.0000081399.75231.3B","article-title":"Tacrolimus enhances transforming growth factor-\u03b21 expression and promotes tumor progression","volume":"76","author":"Maluccio","year":"2003","journal-title":"Transplantation"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","article-title":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transpl. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e14957","DOI":"10.1111\/ctr.14957","article-title":"Safety and efficacy of everolimus initiation from the first month after liver transplantation: A systematic review and meta-analysis","volume":"37","author":"Cholongitas","year":"2023","journal-title":"Clin. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.hbpd.2022.10.004","article-title":"A mixed blessing for liver transplantation patients\u2014Rapamycin","volume":"22","author":"Fan","year":"2023","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/apt.15253","article-title":"Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fphar.2016.00387","article-title":"Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature","volume":"7","author":"Tarantino","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.transproceed.2019.01.069","article-title":"Trough Levels of Everolimus Are Associated with Recurrence Rates of Hepatocellular Carcinoma after Liver Transplantation","volume":"51","author":"Cholongitas","year":"2019","journal-title":"Transplant. Proc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0000000000001894","article-title":"Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma after Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics","volume":"266","author":"Bodzin","year":"2017","journal-title":"Ann. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/2050640619840221","article-title":"Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre","volume":"7","author":"Foerster","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/MEG.0000000000001448","article-title":"Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: Clinical profile and prognostic factors of survival","volume":"31","author":"Chagas","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1245\/s10434-014-4273-6","article-title":"Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series","volume":"22","author":"Sapisochin","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2021.0217","article-title":"The management of post-transplantation recurrence of hepatocellular carcinoma","volume":"28","author":"Rajendran","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","article-title":"Sorafenib (BAY 43-9006, Nexavar\u00ae), a Dual-Action Inhibitor That Targets RAF\/MEK\/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR\/PDGFR in Tumor Vasculature","volume":"Volume 407","author":"Adnane","year":"2006","journal-title":"Methods in Enzymology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jhep.2013.02.026","article-title":"Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study","volume":"59","author":"Sposito","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.dld.2015.01.001","article-title":"Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis","volume":"47","author":"Mancuso","year":"2015","journal-title":"Dig. Liver Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/TP.0000000000003998","article-title":"De Novo Malignancy after Liver Transplantation: Risk Assessment, Prevention, and Management\u2014Guidelines from the ILTS-SETH Consensus Conference","volume":"106","author":"Colmenero","year":"2022","journal-title":"Transplantation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101514","DOI":"10.1016\/j.clinre.2020.07.019","article-title":"Risk factors of de novo malignancies after liver transplantation: A French national study on 11,004 adult patients","volume":"45","author":"Altieri","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/TP.0000000000001438","article-title":"Use of Everolimus in Liver Transplantation: Recommendations From a Working Group","volume":"101","author":"Fagiuoli","year":"2017","journal-title":"Transplantation"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Bzeizi, K.I., Abdullah, M., Vidyasagar, K., Alqahthani, S.A., and Broering, D. (2022). Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence. Cancers, 14.","DOI":"10.3390\/cancers14205114"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/SLA.0000000000002650","article-title":"No Gains in Long-term Survival after Liver Transplantation Over the Past Three Decades","volume":"269","author":"Rana","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic Renal Failure after Transplantation of a Nonrenal Organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Tsochatzis","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/lt.26387","article-title":"Sirolimus or Everolimus Improves Survival after Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"28","author":"Yan","year":"2022","journal-title":"Liver Transplant."},{"key":"ref_84","first-page":"366","article-title":"Liver Transplantation in the Ciclosporin Era","volume":"38","author":"Starzl","year":"1986","journal-title":"Prog. Allergy"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1517\/13543784.8.8.1239","article-title":"Tacrolimus in liver transplantation","volume":"8","author":"Komolmit","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_86","first-page":"356","article-title":"The side-effects of ciclosporine-A and tacrolimus","volume":"49","author":"Mihatsch","year":"1998","journal-title":"Clin. Nephrol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s12072-020-10091-5","article-title":"Immunosuppressive regimens for adult liver transplant recipients in real-life practice: Consensus recommendations from an Italian Working Group","volume":"14","author":"Cillo","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin Inhibitor Nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e12863","DOI":"10.1111\/ctr.12863","article-title":"Impact of acute kidney injury following liver transplantation on long-term outcomes","volume":"31","author":"Trinh","year":"2017","journal-title":"Clin. Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jcph.1334","article-title":"Effects of Conversion from Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients","volume":"59","author":"Tsai","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/hep.23835","article-title":"Use of Sirolimus in Liver Transplant Recipients with Renal Insufficiency: Systematic Review and Meta-Analysis","volume":"52","author":"Asrani","year":"2010","journal-title":"Hepatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100655","DOI":"10.1016\/j.trre.2021.100655","article-title":"An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients","volume":"36","author":"Saliba","year":"2022","journal-title":"Transplant. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jceh.2017.10.003","article-title":"Acute and Chronic Rejection after Liver Transplantation: What A Clinician Needs to Know","volume":"7","author":"Choudhary","year":"2017","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/ajt.14623","article-title":"Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study","volume":"18","author":"Jeng","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial","volume":"15","author":"Metselaar","year":"2009","journal-title":"Liver Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.transproceed.2010.02.011","article-title":"Rescue Immunosuppression with Mammalian Target of Rapamycin Inhibitor Drugs in Liver Transplantation","volume":"42","author":"Pulido","year":"2010","journal-title":"Transplant. Proc."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","article-title":"Regulation of Immune Responses by mTOR","volume":"30","author":"Powell","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/jlts.2003.50079","article-title":"Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications","volume":"9","author":"Dunkelberg","year":"2003","journal-title":"Liver Transplant."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cam4.150","article-title":"Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma\u2014Systematic review and meta-analysis","volume":"2","author":"Yamanaka","year":"2013","journal-title":"Cancer Med."},{"key":"ref_102","first-page":"813","article-title":"Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation","volume":"42","author":"Nguyen","year":"2019","journal-title":"Drug Saf."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.TP.0000128628.31556.B1","article-title":"A Retrospective Review of Liver Transplant Patients Treated with Sirolimus from a Single Center: An Analysis of Sirolimus-Related Complications","volume":"78","author":"Montalbano","year":"2004","journal-title":"Transplantation"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Plotogea, O., Ilie, M., Sandru, V., Chiotoroiu, A., Bratu, O., and Diaconu, C. (2019). Cardiovascular and Metabolic Consequences of Liver Transplantation: A Review. Medicina, 55.","DOI":"10.3390\/medicina55080489"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"845438","DOI":"10.1155\/2014\/845438","article-title":"The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence","volume":"2014","author":"Klintmalm","year":"2014","journal-title":"J. Transplant."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.mayocp.2012.02.021","article-title":"Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know","volume":"87","author":"Singh","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"14959","DOI":"10.1038\/srep14959","article-title":"Paradoxical effect of rapamycin on inflammatory stress-induced insulin resistance in vitro and in vivo","volume":"5","author":"Yang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1083\/jcb.201403080","article-title":"Glucose uptake in brown fat cells is dependent on mTOR complex 2\u2013promoted GLUT1 translocation","volume":"207","author":"Olsen","year":"2014","journal-title":"J. Cell Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1038\/ncomms11365","article-title":"Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism","volume":"7","author":"Tang","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s13300-018-0374-8","article-title":"Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment","volume":"9","author":"Gaete","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: A critical review of the literature","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.14212","article-title":"Efficacy and Safety of Everolimus and Mycophenolic Acid with Early Tacrolimus Withdrawal after Liver Transplantation: A Multicenter Randomized Trial","volume":"17","author":"Saliba","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"9429265","DOI":"10.1155\/2018\/9429265","article-title":"Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians","volume":"2018","author":"Khalil","year":"2018","journal-title":"J. Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.intimp.2004.09.017","article-title":"Center experience in liver transplantation (LTX): Management of dermal side effects caused by sirolimus","volume":"5","author":"Schaffellner","year":"2005","journal-title":"Int. Immunopharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1188\/11.CJON.E83-E89","article-title":"Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors","volume":"15","author":"Pilotte","year":"2011","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2010.01232.x","article-title":"mTOR inhibitor-associated dermatologic and mucosal problems","volume":"24","author":"Campistol","year":"2010","journal-title":"Clin. Transplant."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/6\/421\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:25Z","timestamp":1760125885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/6\/421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":118,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["curroncol30060421"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30060421","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}